Latest News

A drug maker courted controversy when it shut out a family-run rival. Now some patients say the medicine isn’t working

Last February, Barbara Moore switched to a new medicine to combat a rare neuromuscular disease that had plagued her for nearly a quarter of a century.

She had not planned to do so, but Moore had no choice: An effective treatment she had been taking all those years was forced off the market. In late 2018, Catalyst Pharmaceuticals (CPRX) was granted exclusive marketing rights to sell its new drug, called Firdapse, after the Food and Drug Administration approved the medicine. The move precludes any competition for seven years.

Read the rest…

Source link

Related posts

Tallaght University Hospital NCHD Opportunities – July 2019 In Take


Reward improves visual perceptual learning—but only after people sleep


New Abingworth fund beats expectations


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy